Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciluprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.75 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciluprevir SCHEMBL1736294 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL12300089 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL16199312 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL5152276 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL18671856 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL5152261 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL16438974 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL2524642 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL13915576 | 0.96 | ADRB3 (0.70) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL12154816 | 0.96 | ADRB3 (0.69) | ADRB3ADRA2BADRA2CCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060068007-A1 | Class of surfactant-like materials | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | claimed |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| US-11572565-B2 | Inducible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-07 | — | — | US | disclosed |
| US-11530246-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220025381-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-01-27 | — | — | US | disclosed |
| US-11059864-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200308234-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20060068007-A1 | Class of surfactant-like materials | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| US-20040229777-A1 | Crystalline phases of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
| WO-2004087741-A1 | CRYSTALLINE PHASES OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059864-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | ADRB3 3737/4885ADRA2B 3371/4885ADRA2C 3962/4885 |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | ADRB3 4589/4885ADRA2B 4590/4885ADRA2C 4561/4885 |
| US-20040229777-A1 | Crystalline phases of a potent HCV inhibitor | HAVCR2, HCCS, PYGL | ADRB3 4221/4885ADRA2B 4321/4885ADRA2C 3824/4885 |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | ADRB3 1837/4885ADRA2B 2016/4885ADRA2C 2396/4885 |
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | ADRB3 1925/4885ADRA2B 2727/4885ADRA2C 2803/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | ADRB3 1423/4885ADRA2B 1976/4885ADRA2C 1911/4885 |
| US-20060068007-A1 | Class of surfactant-like materials | SMURF1, SMURF2, EBPL | ADRB3 3350/4885ADRA2B 3720/4885ADRA2C 3936/4885 |
| US-11530246-B2 | Regulated synthetic gene expression systems | SRRT, BPTF, MYCBP | ADRB3 4589/4885ADRA2B 4590/4885ADRA2C 4561/4885 |
| US-20200308234-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | ADRB3 3737/4885ADRA2B 3371/4885ADRA2C 3962/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | ADRB3 4070/4885ADRA2B 4543/4885ADRA2C 4304/4885 |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | ADRB3 4589/4885ADRA2B 4590/4885ADRA2C 4561/4885 |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | CTRL, PEPD, PRCP | ADRB3 3161/4885ADRA2B 2445/4885ADRA2C 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.